SuperworthGRAIL GRAL
- Market cap
- $5.9B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 35.8×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $165.3M
- +23% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −5.0%
GRAIL trades at 35.8× sales. Its trailing earnings are negative, so it has no PE. Revenue was $165.3M over the last twelve months, up 23% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $20.7M | $30.3M | $26.7M+36% | $32M+43% | $28.7M+38% | $38.3M+26% | $31.8M+19% | $35.5M+11% | $36.2M+26% | $43.6M+14% | $40.8M+28% | $44.7M+26% | |
| Cost of revenue | n/a | n/a | $15.2M | $16.4M | $17.4M | $20.7M | $18.3M+21% | $19.8M+21% | $16.5M−6% | $21.3M+3% | $21.6M+18% | $23.8M+20% |
| Gross profit | n/a | n/a | $11.6M | $15.6M | $11.2M | $17.5M | $13.5M+17% | $15.7M+1% | $19.7M+76% | $22.3M+28% | $19.2M+42% | $20.9M+33% |
| R&D | $80.1M | $84.1M | $101.6M+18% | $94.2M+6% | $78.2M−2% | $48.3M−43% | $53.6M−47% | $46.6M−51% | $48.6M−38% | $46.9M−3% | $48M−11% | $47.4M+2% |
| SG&A | $86.8M | $91.9M | $103.9M+12% | $108.2M+19% | $83M−4% | $72.6M−21% | $80.1M−23% | $66.5M−39% | $62.9M−24% | $66.4M−9% | $73.4M−8% | $88.4M+33% |
| −$912.4M | −$194.6M | −$227.4M+12% | −$1.6B+703% | −$183.5M−80% | −$136.9M−30% | −$153.6M−33% | −$158.9M−90% | −$125.3M−32% | −$124.4M−9% | −$135.8M−12% | −$173.8M+9% | |
| Pre-tax income | −$910.1M | −$193M | −$224.5M+11% | −$1.6B+708% | −$172.4M−81% | −$127M−34% | −$146.4M−35% | −$152.9M−91% | −$118.7M−31% | −$116.5M−8% | −$127.5M−13% | −$166.7M+9% |
| −$18.6M | −$5.5M | −$5.6M−31% | −$53.1M+443% | −$46.7M+151% | −$29.9M+444% | −$40.2M+622% | −$38.9M−27% | −$29.7M−36% | −$17.3M−42% | −$34.3M−15% | −$56.5M+45% | |
| Net income | −$891.4M | −$187.5M | −$218.9M+13% | −$1.6B+721% | −$125.7M−86% | −$97.1M−48% | −$106.2M−52% | −$114M−93% | −$89M−29% | −$99.2M+2% | −$93.2M−12% | −$110.2M−3% |
| −$28.71 | −$6.04 | −$7.05+13% | −$51.06+721% | −$3.94−86% | −$2.89−52% | −$3.10−56% | −$3.18−94% | −$2.46−38% | −$2.44−16% | −$2.29−26% | −$2.56−20% | |
| 31M | 31M | 31M+0% | 31M+0% | 31.9M+3% | 33.6M+8% | 34.3M+11% | 35.8M+15% | 36.1M+13% | 40.7M+21% | 40.6M+19% | 43.1M+20% |
Revenue: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Gross profit: 9 periods, Q1 FY24 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
SG&A: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Operating income: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Income tax: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
Net income: Q1 FY23 and Q1 FY24: 6 months less the 3 months printed beside them.
EPS, diluted: 5 periods, Q1 FY23 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY23 and Q1 FY24: share-days: the 6-month average less the second quarter's. 3 periods, Q4 FY23 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest GRAIL's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GRALGRAIL | $5.9B | n/m | n/a | n/m | 35.8× | +23% | n/m |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | n/m | 4.2× | +2% | 17.7% |
| BLLNBillionToOne | $5.1B | 166× | 151× | n/m | 12.8× | +90% | 9.5% |
| CAICaris Life Sciences | $9B | 86.5× | 73.7× | n/m | 9.1× | +85% | 10.6% |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | n/m | 6.9× | +17% | 20.4% |
| CDNACareDx | $3.6B | 33.4× | 19.1× | n/m | 7.8× | +34% | 24.2% |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | n/m | 3.8× | +1% | 8.6% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| Peer median | $9.5B | 36.7× | 32.6× | 17.4× | 6.4× | +13% | 10.1% |
Investors who own it
Investors we follow who held GRAIL at the end of Jun 30, 2026, from their 13F filings.
- Ron BaronBaron Capital0.0% of portfoliotrimmed
More on GRAIL
Each number over time
Where it ranks
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .